LCMS
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike

Characterization of C-terminal and Disulfide Bond Peptides of Monoclonal Antibody (mAb) on Q-TOF Mass Spectrometer

 

Similar PDF

Toggle
WP 039 Characterization of Monoclonal Antibody Biosimilar through C-terminal and Disulfide Bond Peptides Sequencing Analysis on Q-TOF Mass Spectrometer Udi Jumhawan and Zhaoqi Zhan Application Development & Support Centre, Shimadzu (Asia Pacific) Pte Ltd, 79 Science Park Drive, Singapore 1.…
Key words
terminal, terminalpeptides, peptidescysteine, cysteinesequencing, sequencingvyacevthqglssp, vyacevthqglsspvtk, vtkdisulfide, disulfidebiosimilar, biosimilarvyacevthqglsspvtk, vyacevthqglsspvtkhinge, hingemapping, mappingdtt, dttbond, bondlinked, linkedcontaining
Application News Biopharma / LCMS-9030 (Q-TOF) Disulfide Bond Characterization of Monoclonal Antibody (mAb) Using Q-TOF Mass Spectrometer No. AD-0214 Yonghai Lu and Zhaoqi Zhan Application Development & Support Centre, Shimadzu (Asia Pacific), Singapore ❑ Introduction Monoclonal antibody (mAb) is emerging…
Key words
disulfide, disulfidebond, bondnovo, novobiosimilar, biosimilarchain, chainpeptide, peptidemab, mabsequencing, sequencingreduced, reducednews, newslinkages, linkagesbevacizumab, bevacizumablcms, lcmsadduct, adductbonds
Application News AD-0176 Biopharma / Nexera Bio & Q-TOF LCMS-9030 Peptide Mapping of Monoclonal Antibody (mAb) Using Nexera Bio with Q-TOF Mass Spectrometer for Full Sequence Confirmation Udi Jumhawan, Wan Tung Liw, Jie Xing and Zhaoqi Zhan Application Development &…
Key words
nexera, nexerapeak, peakbio, biotryptic, trypticbiosimilar, biosimilarbevacizumab, bevacizumabpeptide, peptideantibody, antibodyuhplc, uhplcdigests, digestsigg, iggmin, minnews, newsmapping, mappingbiosimilars
RES MS analysis of antibodies at the protein and peptide levels is critical during development and production of biopharmaceuticals. The compositions of current generation therapeutic proteins are often complex due to their heterogeneity caused by various modifications which are relevant…
Key words
abundance, abundancelys, lystrastuzumab, trastuzumabrelative, relativeinfliximab, infliximabdisulfide, disulfidenative, nativebevacizumab, bevacizumabzoom, zoomxtract, xtractslslspgkc, slslspgkcslslspg, slslspgchain, chainintact, intactreduced
Other projects
Follow us
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike